nach oben

Current Cardiology Reports

Erschienen in:

23.11.2023 | Nuclear Cardiology (V Dilsizian, Section Editor)

The Brain–Heart Axis: Neuroinflammatory Interactions in Cardiovascular Disease

verfasst von: Jiun-Ruey Hu, Ahmed Abdullah, Michael G. Nanna, Robert Soufer

Erschienen in: Current Cardiology Reports | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The role of neuroimmune modulation and inflammation in cardiovascular disease has been historically underappreciated. Physiological connections between the heart and brain, termed the heart-brain axis (HBA), are bidirectional, occur through a complex network of autonomic nerves/hormones and cytokines, and play important roles in common disorders.

Recent Findings

At the molecular level, advances in the past two decades reveal complex crosstalk mediated by the sympathetic and parasympathetic nervous systems, the renin-angiotensin aldosterone and hypothalamus-pituitary axes, microRNA, and cytokines. Afferent pathways amplify proinflammatory signals via the hypothalamus and brainstem to the periphery, promoting neurogenic inflammation. At the organ level, while stress-mediated cardiomyopathy is the prototypical disorder of the HBA, cardiac dysfunction can result from a myriad of neurologic insults including stroke and spinal injury. Atrial fibrillation is not necessarily a causative factor for cardioembolic stroke, but a manifestation of an abnormal atrial substrate, which can lead to the development of stroke independent of AF.

Summary

Central and peripheral neurogenic proinflammatory factors have major roles in the HBA, manifesting as complex bi-directional relationships in common conditions such as stroke, arrhythmia, and cardiomyopathy.

Pavlov VA, Chavan SS, Tracey KJ. Molecular and functional neuroscience in immunity. Annu Rev Immunol. 2018;36:783–812. https://doi.org/10.1146/annurev-immunol-042617-053158.CrossRefPubMedPubMedCentral

Pereira VH, Cerqueira JJ, Palha JA, Sousa N. Stressed brain, diseased heart: a review on the pathophysiologic mechanisms of neurocardiology. Int J Cardiol. 2013;166(1):30–7. https://doi.org/10.1016/j.ijcard.2012.03.165.CrossRefPubMed

Rijkers K, Majoie HJ, Hoogland G, Kenis G, De Baets M, Vles JS. The role of interleukin-1 in seizures and epilepsy: a critical review. Exp Neurol. 2009;216(2):258–71. https://doi.org/10.1016/j.expneurol.2008.12.014.CrossRefPubMed

Liu T, Young PR, McDonnell PC, White RF, Barone FC, Feuerstein GZ. Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral ischemia. Neurosci Lett. 1993;164(1–2):125–8. https://doi.org/10.1016/0304-3940(93)90873-j.CrossRefPubMed

Yu Y, Zhang ZH, Wei SG, Chu Y, Weiss RM, Heistad DD, et al. Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. Circ Res. 2007;101(3):304–12. https://doi.org/10.1161/CIRCRESAHA.107.148940.CrossRefPubMed

Scherbakov N, Doehner W. Heart-brain interactions in heart failure. Card Fail Rev. 2018;4(2):87–91. https://doi.org/10.15420/cfr.2018.14.2.CrossRefPubMedPubMedCentral

Winklewski PJ, Radkowski M, Wszedybyl-Winklewska M, Demkow U. Brain inflammation and hypertension: the chicken or the egg? J Neuroinflammation. 2015;12:85. https://doi.org/10.1186/s12974-015-0306-8.CrossRefPubMedPubMedCentral

Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130. https://doi.org/10.1016/j.ajpc.2020.100130.CrossRefPubMedPubMedCentral

Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293–301. https://doi.org/10.1016/S0140-6736(23)00215-5.CrossRefPubMed

10.

• Badoer E. New insights into the role of inflammation in the brain in heart failure. Front Physiol. 2022;13:837723. https://doi.org/10.3389/fphys.2022.837723. This paper reviews the influence of circulating, proinflammatory cytokines on cardiac function beyond the cardiovascular system, including brain activation of the sympathetic nervous system.CrossRefPubMedPubMedCentral

11.

Chan SH, Chan JY. Angiotensin-generated reactive oxygen species in brain and pathogenesis of cardiovascular diseases. Antioxid Redox Signal. 2013;19(10):1074–84. https://doi.org/10.1089/ars.2012.4585.CrossRefPubMed

12.

Paton JF, Waki H. Is neurogenic hypertension related to vascular inflammation of the brainstem? Neurosci Biobehav Rev. 2009;33(2):89–94. https://doi.org/10.1016/j.neubiorev.2008.05.020.CrossRefPubMed

13.

Saavedra JM, Angiotensin II. AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond). 2012;123(10):567–90. https://doi.org/10.1042/CS20120078.CrossRefPubMed

14.

Wu KL, Chan SH, Chan JY. Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J Neuroinflammation. 2012;9:212. https://doi.org/10.1186/1742-2094-9-212.CrossRefPubMedPubMedCentral

15.

de Kloet AD, Krause EG, Shi PD, Zubcevic J, Raizada MK, Sumners C. Neuroimmune communication in hypertension and obesity: a new therapeutic angle? Pharmacol Ther. 2013;138(3):428–40. https://doi.org/10.1016/j.pharmthera.2013.02.005.CrossRefPubMedPubMedCentral

16.

Dampney RA, Horiuchi J, Killinger S, Sheriff MJ, Tan PS, McDowall LM. Long-term regulation of arterial blood pressure by hypothalamic nuclei: some critical questions. Clin Exp Pharmacol Physiol. 2005;32(5–6):419–25. https://doi.org/10.1111/j.1440-1681.2005.04205.x.CrossRefPubMed

17.

Esler M. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension. Exp Physiol. 2011;96(7):611–22. https://doi.org/10.1113/expphysiol.2010.052332.CrossRefPubMed

18.

Takahashi H. Upregulation of the renin-angiotensin-aldosterone-ouabain system in the brain is the core mechanism in the genesis of all types of hypertension. Int J Hypertens. 2012;2012:242786. https://doi.org/10.1155/2012/242786.CrossRefPubMedPubMedCentral

19.

Kasparov S, Teschemacher AG. Altered central catecholaminergic transmission and cardiovascular disease. Exp Physiol. 2008;93(6):725–40. https://doi.org/10.1113/expphysiol.2007.041814.CrossRefPubMed

20.

Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol. 2010;61(5):509–21.PubMed

21.

Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000;36(2):282–90. https://doi.org/10.1161/01.hyp.36.2.282.CrossRefPubMed

22.

Paton JF, Wang S, Polson JW, Kasparov S. Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. J Mol Med (Berl). 2008;86(6):705–10. https://doi.org/10.1007/s00109-008-0324-4.CrossRefPubMed

23.

Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience. 2010;171(3):852–8. https://doi.org/10.1016/j.neuroscience.2010.09.029.CrossRefPubMed

24.

Guillot FL, Audus KL. Angiotensin peptide regulation of bovine brain microvessel endothelial cell monolayer permeability. J Cardiovasc Pharmacol. 1991;18(2):212–8. https://doi.org/10.1097/00005344-199108000-00006.CrossRefPubMed

25.

Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29(3):640–7. https://doi.org/10.1038/jcbfm.2008.158.CrossRefPubMed

26.

Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension. 2014;63(3):572–9. https://doi.org/10.1161/HYPERTENSIONAHA.113.01743.CrossRefPubMed

27.

Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J. Angiotensin II-induced hypertension is modulated by nuclear factor-kappaB in the paraventricular nucleus. Hypertension. 2012;59(1):113–21. https://doi.org/10.1161/HYPERTENSIONAHA.111.182154.

28.

Felder RB, Yu Y, Zhang ZH, Wei SG. Pharmacological treatment for heart failure: a view from the brain. Clin Pharmacol Ther. 2009;86(2):216–20. https://doi.org/10.1038/clpt.2009.117.CrossRefPubMed

29.

Felder RB. Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp Physiol. 2010;95(1):19–25. https://doi.org/10.1113/expphysiol.2008.045948.CrossRefPubMed

30.

Shi Z, Gan XB, Fan ZD, Zhang F, Zhou YB, Gao XY, et al. Inflammatory cytokines in paraventricular nucleus modulate sympathetic activity and cardiac sympathetic afferent reflex in rats. Acta Physiol (Oxf). 2011;203(2):289–97. https://doi.org/10.1111/j.1748-1716.2011.02313.x.CrossRefPubMed

31.

Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino-Teixeira A, Sousa T. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol. 2021;12:746494. https://doi.org/10.3389/fphys.2021.746494.CrossRefPubMedPubMedCentral

32.

Xu B, Zheng H, Patel KP. Enhanced activation of RVLM-projecting PVN neurons in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2012;302(8):H1700–11. https://doi.org/10.1152/ajpheart.00722.2011.CrossRefPubMedPubMedCentral

33.

Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060–7. https://doi.org/10.1161/01.cir.102.25.3060.CrossRefPubMed

34.

Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002;53(4):822–30. https://doi.org/10.1016/s0008-6363(01)00503-x.CrossRefPubMed

35.

Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594–602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2.CrossRefPubMed

36.

Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392–401. https://doi.org/10.1016/j.jacc.2018.03.002.CrossRefPubMed

37.

Ghaddar B, Diotel N. Zebrafish: a new promise to study the impact of metabolic disorders on the brain. Int J Mol Sci. 2022;23(10). https://doi.org/10.3390/ijms23105372.

38.

Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292(18):2237–42. https://doi.org/10.1001/jama.292.18.2237.CrossRefPubMed

39.

Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab. 2013;2(4):356–63. https://doi.org/10.1016/j.molmet.2013.09.005.CrossRefPubMedPubMedCentral

40.

Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS ONE. 2010;5(4):e10099. https://doi.org/10.1371/journal.pone.0010099.CrossRefPubMedPubMedCentral

41.

Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A. 1999;96(26):15239–44. https://doi.org/10.1073/pnas.96.26.15239.CrossRefPubMedPubMedCentral

42.

• Bhusal A, Rahman MH, Suk K. Hypothalamic inflammation in metabolic disorders and aging. Cell Mol Life Sci. 2021;79(1):32. https://doi.org/10.1007/s00018-021-04019-x. This is a comprehensive review establishing the role of glial cells in the causal relationship between hypothalamic inflammation and the development of metabolic diseases, such as hypertension, obesity, and diabetes.CrossRefPubMed

43.

Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. Circulation. 2017;135(24):2426–41. https://doi.org/10.1161/circulationaha.116.027121.CrossRefPubMed

44.

Nef HM, Möllmann H, Akashi YJ, Hamm CW. Mechanisms of stress (Takotsubo) cardiomyopathy. Nat Rev Cardiol. 2010;7(4):187–93. https://doi.org/10.1038/nrcardio.2010.16.CrossRefPubMed

45.

Chen Z, Venkat P, Seyfried D, Chopp M, Yan T, Chen J. Brain–heart interaction. Circ Res. 2017;121(4):451–68. https://doi.org/10.1161/circresaha.117.311170.CrossRefPubMedPubMedCentral

46.

Fure B, Bruun Wyller T, Thommessen B. Electrocardiographic and troponin T changes in acute ischaemic stroke. J Intern Med. 2006;259(6):592–7. https://doi.org/10.1111/j.1365-2796.2006.01639.x.CrossRefPubMed

47.

Khechinashvili G, Asplund K. Electrocardiographic changes in patients with acute stroke: a systematic review. cerebrovascular diseases. 2002;14(2):67–76. https://doi.org/10.1159/000064733.

48.

Yperzeele L, Van Hooff R-J, Nagels G, De Smedt A, De Keyser J, Brouns R. Heart rate variability and baroreceptor sensitivity in acute stroke: a systematic review. Int J Stroke. 2015;10(6):796–800. https://doi.org/10.1111/ijs.12573.CrossRefPubMed

49.

Park H-K, Kim BJ, Yoon C-H, Yang MH, Han M-K, Bae H-J. Left ventricular diastolic dysfunction in ischemic stroke: functional and vascular outcomes. J Stroke. 2016;18(2):195–202. https://doi.org/10.5853/jos.2015.01697.CrossRefPubMedPubMedCentral

50.

Prosser J, Macgregor L, Lees KR, Diener H-C, Hacke W, Davis S. Predictors of early cardiac morbidity and mortality after ischemic stroke. Stroke. 2007;38(8):2295–302. https://doi.org/10.1161/strokeaha.106.471813.CrossRefPubMed

51.

Gauberti M, Montagne A, Quenault A, Vivien D. Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci. 2014;8:389. https://doi.org/10.3389/fncel.2014.00389.CrossRefPubMedPubMedCentral

52.

van der Bilt IA, Vendeville JP, van de Hoef TP, Begieneman MP, Lagrand WK, Kros JM, et al. Myocarditis in patients with subarachnoid hemorrhage: a histopathologic study. J Crit Care. 2016;32:196–200. https://doi.org/10.1016/j.jcrc.2015.12.005.CrossRefPubMed

53.

Qiang L, Hong L, Ningfu W, Huaihong C, Jing W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol. 2013;168(3):2082–8. https://doi.org/10.1016/j.ijcard.2013.01.160.CrossRefPubMed

54.

Wang S, Aurora AB, Johnson BA, Qi X, Mcanally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71. https://doi.org/10.1016/j.devcel.2008.07.002.CrossRefPubMedPubMedCentral

55.

Long G, Wang F, Li H, Yin Z, Sandip C, Lou Y, et al. Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans. BMC Neurol. 2013;13(1):178. https://doi.org/10.1186/1471-2377-13-178.CrossRefPubMedPubMedCentral

56.

Chen J, Cui C, Yang X, Xu J, Venkat P, Zacharek A, et al. MiR-126 affects brain-heart interaction after cerebral ischemic stroke. Transl Stroke Res. 2017;8(4):374–85. https://doi.org/10.1007/s12975-017-0520-z.CrossRefPubMedPubMedCentral

57.

Lackner P, Dietmann A, Beer R, Fischer M, Broessner G, Helbok R, et al. Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. Stroke. 2010;41(10):2353–7. https://doi.org/10.1161/strokeaha.110.584995.CrossRefPubMed

58.

Schoch B, Regel JP, Wichert M, Gasser T, Volbracht L, Stolke D. Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery. 2007;60(5):828–36; discussion -36. https://doi.org/10.1227/01.NEU.0000255440.21495.80.

59.

Wilbert-Lampen U, Leistner D, Greven S, Pohl T, Sper S, Völker C, et al. Cardiovascular events during World Cup Soccer. N Engl J Med. 2008;358(5):475–83. https://doi.org/10.1056/nejmoa0707427.CrossRefPubMed

60.

Rozanski A, Bairey CN, Krantz DS, Friedman J, Resser KJ, Morell M, et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med. 1988;318(16):1005–12. https://doi.org/10.1056/nejm198804213181601.CrossRefPubMed

61.

Goldberg AD, Bonsall R, Cohen JD, Ketterer MW, Kaufman PG, Krantz DS, et al. Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia Study (PIMI). Circulation. 1996;94(10):2402–9. https://doi.org/10.1161/01.cir.94.10.2402.

62.

Lazzarino AI, Hamer M, Gaze D, Collinson P, Steptoe A. The association between cortisol response to mental stress and high-sensitivity cardiac troponin T plasma concentration in healthy adults. J Am Coll Cardiol. 2013;62(18):1694–701. https://doi.org/10.1016/j.jacc.2013.05.070.CrossRefPubMedPubMedCentral

63.

Wilbert-Lampen U, Nickel T, Leistner D, Guthlin D, Matis T, Volker C, et al. Modified serum profiles of inflammatory and vasoconstrictive factors in patients with emotional stress-induced acute coronary syndrome during World Cup Soccer 2006. J Am Coll Cardiol. 2010;55(7):637–42. https://doi.org/10.1016/j.jacc.2009.07.073.CrossRefPubMed

64.

Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352(6):539–48. https://doi.org/10.1056/nejmoa043046.CrossRefPubMed

65.

Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30–8. https://doi.org/10.1038/nrcardio.2016.163.CrossRefPubMed

66.

Freeman R. Cardiovascular manifestations of autonomic epilepsy. Clin Auton Res. 2006;16(1):12–7. https://doi.org/10.1007/s10286-006-0278-y.CrossRefPubMed

67.

Tinuper P, Bisulli F, Cerullo A, Carcangiu R, Marini C, Pierangeli G, et al. Ictal bradycardia in partial epileptic seizures: autonomic investigation in three cases and literature review. Brain. 2001;124(12):2361–71. https://doi.org/10.1093/brain/124.12.2361.CrossRefPubMed

68.

Furlan JC, Fehlings MG. Cardiovascular complications after acute spinal cord injury: pathophysiology, diagnosis, and management. Neurosurgical Focus FOC. 2008;25(5):E13. https://doi.org/10.3171/FOC.2008.25.11.E13.CrossRef

69.

Park DY, Hu JR, Alexander KP, Nanna MG. Readmission and adverse outcomes after percutaneous coronary intervention in patients with dementia. J Am Geriatr Soc. 2023;71(4):1034–46. https://doi.org/10.1111/jgs.18120.CrossRefPubMed

70.

Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47(3):895–900. https://doi.org/10.1161/strokeaha.115.012004.CrossRefPubMedPubMedCentral

71.

Trayanova NA. Mathematical approaches to understanding and imaging atrial fibrillation: significance for mechanisms and management. Circ Res. 2014;114(9):1516–31. https://doi.org/10.1161/circresaha.114.302240.CrossRefPubMedPubMedCentral

72.

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47. https://doi.org/10.1161/circulationaha.113.005119.CrossRefPubMed

73.

Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 1999;30(10):2019–24. https://doi.org/10.1161/01.str.30.10.2019.CrossRefPubMed

74.

Kamel H, O’Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol. 2015;78(5):670–8. https://doi.org/10.1002/ana.24482.CrossRefPubMedPubMedCentral

75.

Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT, Nazarian S, et al. P-wave morphology and the risk of incident ischemic stroke in the multi-ethnic study of atherosclerosis. Stroke. 2014;45(9):2786–8. https://doi.org/10.1161/strokeaha.114.006364.CrossRefPubMedPubMedCentral

76.

Kamel H, Elkind MSV, Bhave PD, Navi BB, Okin PM, Iadecola C, et al. Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke. 2013;44(6):1550–4. https://doi.org/10.1161/strokeaha.113.001118.CrossRefPubMedPubMedCentral

77.

Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol. 2015;66(3):232–41. https://doi.org/10.1016/j.jacc.2015.05.018.CrossRefPubMed

78.

De Jong AM, Maass AH, Oberdorf-Maass SU, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. 2011;89(4):754–65. https://doi.org/10.1093/cvr/cvq357.CrossRefPubMed

79.

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–9. https://doi.org/10.1056/NEJMoa1105575.CrossRefPubMed

80.

Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1? Stroke. 2012;43(10):2551–5. https://doi.org/10.1161/strokeaha.112.667865.CrossRefPubMed

81.

Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106(22):2854–8. https://doi.org/10.1161/01.cir.0000039327.11661.16.CrossRefPubMed

82.

Warraich HJ, Gandhavadi M, Manning WJ. Mechanical discordance of the left atrium and appendage: a novel mechanism of stroke in paroxysmal atrial fibrillation. Stroke. 2014;45(5):1481–4. https://doi.org/10.1161/strokeaha.114.004800.CrossRefPubMed

83.

Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86. https://doi.org/10.1056/nejmoa1313600.CrossRefPubMed

84.

Budaj A, Flasinska K, Gore JM, Anderson FA Jr, Dabbous OH, Spencer FA, et al. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111(24):3242–7. https://doi.org/10.1161/circulationaha.104.512806.CrossRefPubMed

85.

Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Stroke rates following surgical versus percutaneous coronary revascularization. J Am Coll Cardiol. 2018;72(4):386–98. https://doi.org/10.1016/j.jacc.2018.04.071.CrossRefPubMed

86.

Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. https://doi.org/10.1161/01.str.24.1.35.

87.

Merkler AE, Diaz I, Wu X, Murthy SB, Gialdini G, Navi BB, et al. Duration of heightened ischemic stroke risk after acute myocardial infarction. J Am Heart Assoc. 2018;7(22). https://doi.org/10.1161/jaha.118.010782.

88.

Kotecha T, Rakhit RD. Acute coronary syndromes. Clin Med (Lond). 2016;16(Suppl 6):s43–8. https://doi.org/10.7861/clinmedicine.16-6-s43.CrossRefPubMed

89.

Francis J, Chu Y, Johnson AK, Weiss RM, Felder RB. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol. 2004;286(6):H2264–71. https://doi.org/10.1152/ajpheart.01072.2003.CrossRefPubMed

90.

•• Gelosa P, Castiglioni L, Rzemieniec J, Muluhie M, Camera M, Sironi L. Cerebral derailment after myocardial infarct: mechanisms and effects of the signaling from the ischemic heart to brain. J Mol Med. 2022;100(1):23–41. https://doi.org/10.1007/s00109-021-02154-3. This is a comprehensive review of molecular mechanisms for how cardiac disorders, such as myocardial infarction, can enhance systemic inflammation and alter extracellular vesicles and circulating micro RNAs to cause neurologic dysfunction, including increasing the risk of stroke in MI.CrossRefPubMed

91.

Stellos K, Panagiota V, Kögel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab. 2010;30(11):1817–20. https://doi.org/10.1038/jcbfm.2010.140.CrossRefPubMedPubMedCentral

92.

Ozcan Cetin EH, Cetin MS, Aras D, Topaloglu S, Temizhan A, Kisacik HL, et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST-segment elevation myocardial infarction. Angiology. 2016;67(4):336–45. https://doi.org/10.1177/0003319715591751.CrossRefPubMed

93.

Yang Y, Xie D, Zhang Y. Increased platelet-to-lymphocyte ratio is an independent predictor of hemorrhagic transformation and in-hospital mortality among acute ischemic stroke with large-artery atherosclerosis patients. Int J Gen Med. 2021;14:7545–55. https://doi.org/10.2147/ijgm.S329398.CrossRefPubMedPubMedCentral

94.

Deckers K, Schievink SHJ, Rodriquez MMF, Van Oostenbrugge RJ, Van Boxtel MPJ, Verhey FRJ, et al. Coronary heart disease and risk for cognitive impairment or dementia: Systematic review and meta-analysis. PLoS ONE. 2017;12(9):e0184244. https://doi.org/10.1371/journal.pone.0184244.CrossRefPubMedPubMedCentral

95.

Kasprzak D, Rzeźniczak J, Ganowicz T, Łuczak T, Słomczyński M, Hiczkiewicz J, et al. A review of acute coronary syndrome and its potential impact on cognitive function. Glob Heart. 2021;16(1):53. https://doi.org/10.5334/gh.934.CrossRefPubMedPubMedCentral

96.

Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672–713. https://doi.org/10.1161/STR.0b013e3182299496.CrossRefPubMedPubMedCentral

97.

Abete P, Della-Morte D, Gargiulo G, Basile C, Langellotto A, Galizia G, et al. Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis. Ageing Res Rev. 2014;18:41–52. https://doi.org/10.1016/j.arr.2014.07.003.

98.

Kucheryavykh LY, Davila-Rodriguez J, Rivera-Aponte DE, Zueva LV, Washington AV, Sanabria P, et al. Platelets are responsible for the accumulation of beta-amyloid in blood clots inside and around blood vessels in mouse brain after thrombosis. Brain Res Bull. 2017;128:98–105. https://doi.org/10.1016/j.brainresbull.2016.11.008.CrossRefPubMed

99.

Gagno G, Ferro F, Fluca AL, Janjusevic M, Rossi M, Sinagra G, et al. From brain to heart: possible role of amyloid-β in ischemic heart disease and ischemia-reperfusion injury. Int J Mol Sci. 2020;21(24):9655. https://doi.org/10.3390/ijms21249655.CrossRefPubMedPubMedCentral

100.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. https://doi.org/10.1016/s0092-8674(04)00045-5.CrossRefPubMed

101.

Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. BMC Med Genomics. 2013;6(1):16. https://doi.org/10.1186/1755-8794-6-16.CrossRefPubMedPubMedCentral

102.

Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem. 2012;58(3):559–67. https://doi.org/10.1373/clinchem.2011.173823.CrossRefPubMed

103.

Boštjančič E, Zidar N, Štajer D, Glavač D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010;115(3):163–9. https://doi.org/10.1159/000268088.CrossRefPubMed

104.

105.

Li S, Zhang XH, Zhou GD, Wang JF. Delirium after primary percutaneous coronary intervention in aged individuals with acute ST-segment elevation myocardial infarction: a retrospective study. Exp Ther Med. 2019;17(5):3807–13. https://doi.org/10.3892/etm.2019.7398.CrossRefPubMedPubMedCentral

106.

Cortés-Beringola A, Vicent L, Martín-Asenjo R, Puerto E, Domínguez-Pérez L, Maruri R, et al. Diagnosis, prevention, and management of delirium in the intensive cardiac care unit. Am Heart J. 2021;232:164–76. https://doi.org/10.1016/j.ahj.2020.11.011.CrossRefPubMed

107.

Vives-Borrás M, Martínez-Sellés M, Ariza-Solé A, Vidán MT, Formiga F, Bueno H, et al. Clinical and prognostic implications of delirium in elderly patients with non-ST-segment elevation acute coronary syndromes. J Geriatr Cardiol. 2019;16(2):121–8. https://doi.org/10.11909/j.issn.1671-5411.2019.02.008.CrossRefPubMedPubMedCentral

108.

Silva M, Pereira E, Rocha A, Sousa D, Peixoto B. Neurocognitive impairment after acute coronary syndrome: prevalence and characterization in a hospital-based cardiac rehabilitation program sample. J Cardiovasc Thorac Res. 2018;10(2):70–5. https://doi.org/10.15171/jcvtr.2018.11.CrossRefPubMedPubMedCentral

109.

Hayhurst CJ, Pandharipande PP, Hughes CG. Intensive care unit delirium: a review of diagnosis, prevention, and treatment. Anesthesiology. 2016;125(6):1229–41. https://doi.org/10.1097/aln.0000000000001378.CrossRefPubMed

110.

Sun SH, Yang L, Sun DF, Wu Y, Han J, Liu RC, et al. Effects of vasodilator and esmolol-induced hemodynamic stability on early post-operative cognitive dysfunction in elderly patients: a randomized trial. Afr Health Sci. 2016;16(4):1056–66. https://doi.org/10.4314/ahs.v16i4.23.CrossRefPubMedPubMedCentral

111.

• Park DY, Jamil Y, Hu JR, Lowenstern A, Frampton J, Abdullah A, et al. Delirium in older adults after percutaneous coronary intervention: prevalence, risks, and clinical phenotypes. Cardiovasc Revasc Med. 2023. https://doi.org/10.1016/j.carrev.2023.06.010. This paper outlines the risk of delirium and mortality as poor outcomes after percutaneous intervention in older adults with acute coronary syndrome, underscoring the neuroinflammatory response associated with the periprocedural period.CrossRefPubMed

112.

Wang X, Feng K, Liu H, Liu Y, Ye M, Zhao G, et al. Regional cerebral oxygen saturation and postoperative delirium in endovascular surgery: a prospective cohort study. Trials. 2019;20(1):504. https://doi.org/10.1186/s13063-019-3586-y.CrossRefPubMedPubMedCentral

Titel: The Brain–Heart Axis: Neuroinflammatory Interactions in Cardiovascular Disease
verfasst von: Jiun-Ruey Hu
Ahmed Abdullah
Michael G. Nanna
Robert Soufer
Publikationsdatum: 23.11.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 12/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01990-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Brain–Heart Axis: Neuroinflammatory Interactions in Cardiovascular Disease

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Cardiac Rehabilitation After Hospitalization for Acute Coronary Syndrome

Multi-proteomic Biomarker Risk Scores for Predicting Risk and Guiding Therapy in Patients with Coronary Artery Disease

Surgical Approaches for Pericardial Diseases: What Is New?

Multimodality Imaging Approach Evaluation of the Congenital Pericardial Defect: a Contemporary Review

Cardioneuroablation for the Treatment of Vasovagal Syncope: Current Status and Impact on Quality of Life

Achieving Health Equity in the Care of Patients with Heart Failure

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie